This site is intended for health professionals only

Acquisition boosts Pfizer profits

teaser

Thanks to favourable currency rates and its acquisition of rival Wyeth in October, US pharmaceutical Pfizer has reported a 9% rise in second-quarter profit.

The results came in well ahead of Wall Street forecasts, as revenue rose 58%.

For the three months to July 4 net income rose to $2.48bn (£1.6bn), or 31 cents per share, for the company which produces impotence pill Viagra and cholesterol blockbuster Liptor.

At the same time in 2009, income was $2.26bn, or 34 cents a share. To help pay for the acquisition of Wyeth, Pfizer sold millions of new shares.

Mainly because of $5.4bn from Wyeth products, revenue for the world’s largest drug maker came in at $17.33bn, up from $10.98bn last year. US sales increased 63% and foreign sales shot up 54%.

Excluding 31 cents in one-time items, income was $4.96 billion, or 62 cents a share. Those items included $1.1 billion before taxes for integrating Wyeth’s systems, employee severance and other restructuring, plus $2.1 billion before taxes for various charges related to buying Wyeth.

Analysts surveyed by Thomson Reuters expected 52 cents a share on revenue of $16.65 billion.

Shares rallied 86 cents, or 5.6%, to close at $16.34 on Tuesday.

Wyeth is Pfizer’s third major purchase in nine years. Still, Pfizer is reportedly one of three huge companies interested in US biotech firm Genzyme, if France’s Sanofi-Aventis cannot close on its reported $18 billion offer.

Copyright © Press Association 2010






Be in the know
Subscribe to Hospital Pharmacy Europe newsletter and magazine

x